NWBO News and Press, Northwest Biotherapeutics Inc. From 07/26/22

CytoDyn Inc (OTCMKTS: CYDY) shares gained more than 8% closing the day at $0.73. CYDY has a market cap of over 524.8M$. CYDY is a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications. The company had announced the appointment o...

Northwest Biotherapeutics Announces Filing of Application for License for Commercial Manufacturing at Sawston, UK Facility PR Newswire Application Package Developed By Advent BioServices; Builds on Licenses Obtained in 2021 BETHESDA, Md. , July 6,...

Northwest Biotherapeutics Announces Presentations On DCVax®-L Personalized Vaccines, Manufacturing and Scale-Up, and DCVax®-L Clinical Program PR Newswire BETHESDA, Md. , June 5, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW ...

As the recent Rett syndrome controversy shows, Anavex is a perpetually beleaguered stock. Despite the tremendous bearish headwind it always faces, the company has been able to increase shareholder value over the years. However, AVXL is still a highly risky, high blood pressure sto...

Data is excellent. I explain the bearish commentary here. The stock may go up on NDA announcement and other regulatory steps. For further details see: Northwest Bio: Buy Again, Wait For Regulatory Process

The shares of Northwest Biotherapeutics (OTCQB:NWBO) reached a 52-week low on Tuesday after the clinical-stage immunotherapy company announced a presentation with Phase 3 data for its lead asset DCVax-L in Glioblastoma multiforme (GBM) brain cancer. Northwest (OTCQB:NWBO) develops product can...

Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma Today At New York Academy of Sciences To Be Available Online As Well PR Newswire BETHESDA, Md. , May 10, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechn...

Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma To Be Made At New York Academy Of Sciences PR Newswire BETHESDA, Md. , May 4, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DC...

I have no great opinion about NWBO as a company. However, I am holding a small position, just to see how it ends up. For anyone holding a position, here's an update that could be useful. For further details see: Northwest Bio: What A Comparison Analysis Says About Its Pr...

Northwest Biotherapeutics (OTCQB:NWBO +7.6%) began production of its first dendritic cell cancer vaccine for a compassionate use patient at its production facility in Sawston, U.K. The company said the milestone follows approval by the U.K. Medicines and Healthcare Products Regulatory Ag...